JAGX
Jaguar Health, Inc. · Healthcare
0.41
2.52%(+0.01)
Prev. Close0.49
20.00%(+0.08)
Pre-marketLast Updated: — ET
52W L: $0.3152W H: $15.48
$0.40
CHG-0.16 (-28.64%)
H$0.60
L$0.31
VOL12M
JAGX (1h)
Jaguar Health, Inc. · Healthcare
Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) and Jaguar Animal Health (NASDAQ: JAGX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Profitability This table compares Telomir Pharmaceuticals
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID) suffer from IF, as do a significant proportion of patients with short bowel syndrome (SBS). The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction could potentially reduce co-morbidities and improve clinical benefit, as no approved therapies exist for MVID Jaguar launches news alert text service for investors - click here to sign up for text alerts SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, based on the U.S. Food and Drug Administration (FDA) support for Napo's protocol amendment for its clinical trial to evaluate the safety and efficacy of its novel crofelemer powder-for-oral-solution formulation in pediatric patients with intestinal failure due to MVID, an ultrarare pediatric disorder, Napo plans to initiate a single-blind extension phase for the trial. The extended treatment period has the potential to improve clinical benefit of crofelemer through reduction of parenteral support (PS) requirements, which may result in disease progression-modification of MVID.
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (OTC:FLHLF) ("Filament"), has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management.
Jaguar Animal Health (NASDAQ: JAGX - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Earnings and Valuation This table compares
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com. Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum When: Thursday, March 12, 2026 at 2:00 PM Eastern Registration link for conference: Click Here Replay: A replay of the webcast will be available following the conclusion of the conference.
MICEK JOHN
director
7,377 SH @ $0.00
2025-12-11
MICEK JOHN
director
7,377 SH @ $1.44
2025-12-11
King Steven R.
officer: See Remarks
11,740 SH @ $0.00
2025-12-11
King Steven R.
officer: See Remarks
11,740 SH @ $1.44
2025-12-11
CONTE LISA A
director, officer: See Remarks
28,592 SH @ $0.00
2025-12-11
CONTE LISA A
director, officer: See Remarks
28,592 SH @ $1.44
2025-12-11
Wolin Jonathan S.
officer: See Remarks
11,740 SH @ $0.00
2025-12-11
Wolin Jonathan S.
officer: See Remarks
11,740 SH @ $1.44
2025-12-11